A Case Report of Sinus Bradycardia after the Addition of Lurasidone in a Patient with Bipolar Disorder
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
To date, tachycardia and orthostatic hypotension have been reported as one of the negative cardiovascular complications of antipsychotics. The aim of this study was to report a case of sinus bradycardia caused by the addition of lurasidone. The patient, a 46-year-old bipolar disorder female, was admitted to the Affiliated Brain Hospital of Guangzhou Medical University with 28 years of alternating euphoric and dysphoria. On the basis of lithium carbonate 1,200 mg/day and sodium valproate 1,500 mg/day, the patient was given lurasidone 80 mg/day. After 5 days of medication, her heart rate (HR) became 48 beats per minute (beats/min). As a result, lurasidone treatment was held. On 5th day after discontinuing lurasidone, the HR reached 80 beats/min. This case report notifies that although the cardiovascular effects of lurasidone are not significant, it is also important to monitor HR status after the first administration of lurasidone.
Abstract
To date, tachycardia and orthostatic hypotension have been reported as one of the negative cardiovascular complications of antipsychotics. The aim of this study was to report a case of sinus bradycardia caused by the addition of lurasidone. The patient, a 46-year-old bipolar disorder female, was admitted to the Affiliated Brain Hospital of Guangzhou Medical University with 28 years of alternating euphoric and dysphoria. On the basis of lithium carbonate 1,200 mg/day and sodium valproate 1,500 mg/day, the patient was given lurasidone 80 mg/day. After 5 days of medication, her heart rate (HR) became 48 beats per minute (beats/min). As a result, lurasidone treatment was held. On 5th day after discontinuing lurasidone, the HR reached 80 beats/min. This case report notifies that although the cardiovascular effects of lurasidone are not significant, it is also important to monitor HR status after the first administration of lurasidone.
참고문헌 (25)
- Huang LC, "Amisulpride and symptomatic bradycardia : a case report", Gen Hosp Psychiatry, 37, pp.497~ (2015)
- Ito A, "Two cases of life-threatening arrhythmia induced by risperidone : evaluation of risperidone and 9-hydroxy-risperidone concentrations", Acute Med Surg, 4, pp.341~343 (2017)
- Snarr BS, "Symptomatic bradycardia with oral aripiprazole and oral ziprasidone", Ann Pharmacother, 44, pp.760~763 (2010)
- Sharma N, "Severe hypothermia, bradycardia and cardiac arrest in association with risperidone", BMJ Case Rep, 13, pp.e234999~ (2020)
- Correll CU, "Long-term safety and effectiveness of lurasidone in schizophrenia : a 22-month, open-label extension study", CNS Spectr, 21, pp.393~402 (2016)
- Jaeschke RR, "Lurasidone : the 2016 update on the pharmacology, efficacy and safety profile", Pharmacol Rep, 68, pp.748~755 (2016)
- Naranjo CA, "Advances in the diagnosis of adverse drug reactions", J Clin Pharmacol, 32, pp.897~904 (1992)
- Wu J, "Normal limits of the electrocardiogram in Chinese subjects", Int J Cardiol, 87, pp.37~51 (2003)
- Ovsyshcher IE, "Drug induced bradycardia : to pace or not to pace?", Pacing Clin Electrophysiol, 27, pp.1144~1147 (2004)
- Liu EF, "Sinus bradycardia: normal phenomenon or risk factor? Evaluation based on recent evidence", J Insur Med, 43, pp.102~111 (2012)
- Jordan D, "Vagal control of the heart : central serotonergic(5-HT)mechanisms", Exp Physiol, 90, pp.175~181 (2005)
- Davisson RL, "Effects of intracerebroventricular injections of 5-HT on systemic vascular resistances of conscious rats", Microvasc Res, 95, pp.116~123 (2014)
- Youn J, "Central 5-HT1A receptor-mediated modulation of heart rate dynamics and its adjustment by conditioned and unconditioned fear in mice", Br J Pharmacol, 170, pp.859~870 (2013)
- Hatab SA, "Are 5-HT1A receptors involved in the control of reflex bradycardia induced by intracoronary injection of contrast medium in humans?", Braz J Med Biol Res, 29, pp.769~772 (1996)
- Futuro Neto HA, "Central 5-HT2A receptors modulate the vagal bradycardia in response to activation of the von Bezold-Jarisch reflex in anesthetized rats", Braz J Med Biol Res, 44, pp.224~228 (2011)
- Gorini C, "Serotonergic modulation of the trigeminocardiac reflex neurotransmission to cardiac vagal neurons in the nucleus ambiguus", J Neurophysiol, 102, pp.1443~1450 (2009)
- López C, "Fluoxetine oral treatment discloses 5-HT1D receptor as vagoinhibitor of the cardiac cholinergic neurotransmission in rat", Can J Physiol Pharmacol, 97, pp.90~98 (2019)
- 이종훈, "Prognosis and Natural History of Drug-Related Bradycardia", Korean Circulation Journal, 39(9), pp.367~371 (2009), 대한심장학회
- Sabharwal MS, "Severe bradycardia caused by a single dose of lithium", Intern Med, 52, pp.767~769 (2013)
- Snipes GM, "Sinus bradycardia with haemodynamic compromise following lithium intoxication", BMJ Case Rep, 14, pp.e242946~ (2021)
- Offerman SR, "Hospitalized lithium overdose cases reported to the California Poison Control System", Clin Toxicol(Phila), 48, pp.443~448 (2010)
- Ataallah B, "A rare but reversible cause of lithium-induced bradycardia", Cureus, 12, pp.e8600~ (2020)
- Alamo C, "The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder", Expert Rev Neurother, 14, pp.593~605 (2014)
- Calabrese JR, "Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder", Eur Neuropsychopharmacol, 27, pp.865~876 (2017)
- Loebel A, "Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression : a randomized, doubleblind, placebo-controlled study", Am J Psychiatry, 171, pp.169~177 (2014)